



PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/018,437-Conf. #4498
		Filing Date	June 3, 2002
		First Named Inventor	Uwe Zangemeister-Wittke
		Art Unit	1635
		Examiner Name	T. C. Gibbs
Total Number of Pages in This Submission		Attorney Docket Number	27656/37821

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MARSHALL, GERSTEIN & BORUN LLP		
Signature			
Printed name	Jeffrey S. Sharp		
Date	March 3, 2005	Reg. No.	31,879

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 3, 2005

Signature: (Jeffrey S. Sharp)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date shown below.

Dated: March 3, 2005

Signature:

Jeffrey S. Sharp

Docket No.: 27656/37821
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

ZANGEMEISTER-WITTKE et al.

Application No.: 10/018,437

Group Art Unit: 1635

Filed: June 3, 2002

Examiner: Terra C. Gibbs

For: OLIGONUCLEOTIDE DERIVATIVES
DIRECTED AGAINST HUMAN BCL-XL
AND HUMAN BCL-2 mRNA

**RESPONSE TO EXAMINER'S COMMUNICATION,
RESTRICTION REQUIREMENT
AND AMENDMENT UNDER 37 C.F.R. §1.111**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

This paper is in response to a communication from the Examiner dated February 24, 2005 requesting correction of the response to the Office Action dated November 30, 2004, filed on December 30, 2004, in which claims 1-26 were subjected to a five-way restriction requirement. In response to the request, Applicants elect Group II (claim 2). Applicants also amend claims 3, 4, 7, 8 and 26 such that each of claims 3-18 now depend from elected claim 2 and specify below further restrictions as they were applied by the Examiner against Group I. The current status of all pending claims have been reviewed and addressed as indicated below.

INTRODUCTORY COMMENTS

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

A Current Listing of the Claims begins on Page 2 of this paper.

Remarks begin on Page 8 of this paper.